Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Breye Therapeutics raised a EUR 67.5 million oversubscribed Series A co-led by Novo Holdings with Mission BioCapital. Proceeds support a Phase II trial of danegaptide in non-proliferative diabetic retinopathy starting in 2027 and additional retinal-disease pipeline work.
Breye Therapeutics raised an oversubscribed EUR 67.5 million Series A with Sound Bioventures Management AB, Mission BioCapital and Novo Holdings, targeting a randomized Phase 2 trial of danegaptide in non-proliferative diabetic retinopathy starting in 2027.